GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6399 3-AQCSummary: 5-HT3 antagonist -
B6404 2-PhenylmelatoninSummary: melatonin agonist -
B6423 RS 23597-190 hydrochlorideSummary: 5-HT4 receptor antagonist -
B6428 2-IodomelatoninSummary: melatonin agonist -
B6433 4-IBPSummary: σ1 agonist -
B6435 PG-9 maleateSummary: Increases release of acetylcholine -
B6436 SM-21 maleateSummary: Increases release of acetylcholine,σ2 antagonist -
B6454 Efaroxan hydrochlorideSummary: α2 adrenoceptor antagonist and imidazoline I1 receptor ligand -
B6455 Idazoxan hydrochlorideSummary: α2-adrenoceptor antagonist -
B6464 ICI 89406Summary: β-adrenergic antagonist

